Visceral Leishmaniasis with Hemophagocytic Syndrome in a patient infected by SARS-COV2: a case report

Article Sidebar

PDF
Published: Mar 12, 2025
DOI: https://doi.org/10.7322/abcshs.2023131.2412
Keywords:
Leishmaniasis, Visceral, Syndrome, COVID-19, Lymphohistiocytosis hemophagocytic, SARS-CoV-2, coinfection

Main Article Content

Letícia Vitória Lino Sousa
Departamento de Clínica Médica, Hospital Universitário, Universidade Federal do Maranhão (UFMA) – São Luís (MA), Brazil
Gilnara Fontinelle Barros
Departamento de Clínica Médica, Hospital Universitário, Universidade Federal do Maranhão (UFMA) – São Luís (MA), Brazil
Inggryd Eduarda Possidônio de Souza Santos
Curso de Medicina, UFMA – São Luís (MA), Brazil
Ana Carolina Silva Rocha
Curso de Medicina, UFMA – São Luís (MA), Brazil
Kamilly Ieda Silva Viegas
Curso de Medicina, UFMA – São Luís (MA), Brazil

Abstract

Introduction: Visceral leishmaniasis is a disease that determines a picture of immunosuppression in the patient after contact with infected sandflies. Secondary hemophagocytic syndrome, on the other hand, is an immune-mediated condition that develops after infections, neoplasms, or autoimmune diseases. COVID-19 has infected more than 130 million people and caused more than 2.6 million deaths worldwide. Immunosuppression triggered by COVID-19 can be an aggravating factor for latent infections. Report: This article reported the case of a patient, 37 years old, with a previous history of Severe Acute Respiratory Distress Syndrome due to SARS-COV-2, later diagnosed with Hemophagocytic Syndrome Secondary to Visceral Leishmaniasis. Conclusion: A SARS-CoV-2 pandemic has revealed cases of co-infection with visceral leishmaniasis, highlighting the need for case reports that contribute to the efficiency of diagnosing and treating patients with comorbidities, aiming for a favorable outcome in the clinical condition of the patients.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sousa, L. V. L., Barros, G. F., Santos, I. E. P. de S., Rocha, A. C. S., & Viegas, K. I. S. (2025). Visceral Leishmaniasis with Hemophagocytic Syndrome in a patient infected by SARS-COV2: a case report. ABCS Health Sciences. https://doi.org/10.7322/abcshs.2023131.2412
Issue
Ahead of print
Section
Reports
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY) that allows others to share and adapt the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

References

Wilhelm TJ. [Visceral Leishmaniasis]. Chirurg. 2019;90(10):833-7. https://doi.org/10.1007/s00104-019-0994-1

Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951-70. https://doi.org/10.1016/S0140-6736(18)31204-2

Machelart I, Lapoirie J, Viallard JF, Mirabel M, Lazaro E, Greib C, et al. Visceral leishmaniasis with hemophagocytic lymphohistiocytosis in an immunocompetent adult. Med Mal Infect. 2019;49(7):548-50. https://doi.org/10.1016/j.medmal.2019.07.006

Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-52. https://doi.org/10.1182/blood-2011-03-278127

Milagres ACA, Barbosa GM, Moreira RLF, Mendonça RP, Veloso FQS, Rabelo BL, et al. Apresentação de Leishmaniose Visceral em paciente pós-Covid grave: um relato de caso. Braz J Infect Dis. 2022;26:101784. https://doi.org/10.1016/j.bjid.2021.101784

Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Med Hyg. 2017;96(1):24-45. https://doi.org/10.4269/ajtmh.16-84256

Carvalho SFG, Vieira TM, Moua APV, Andrade MC. Should an intersection between visceral leishmaniasis endemicity and the COVID-19 pandemic be considered? Med Hypotheses. 2020;144:110289. https://doi.org/10.1016/j.mehy.2020.110289

Bamorovat M, Sharifi I, Aflatoonian MR, Karamoozian A, Tahmouresi A, Jafarzadeh A, et al. Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment. Int J Infect Dis. 2022;122:155-61. https://doi.org/10.1016/j.ijid.2021.09.050

Miotti AM, Patacca A, Grosso C, Cristini F. COVID-19 in a Patient with Visceral Leishmaniasis. J Infect Dis Ther. 2020;8(4):430.

Pikoulas A, Piperaki ET, Spanakos G, Kallianos A, Mparmparousi D, Rentziou G, et al. Visceral leishmaniasis and COVID-19 coinfection–a case report. IDCases. 2022;27:e01358. https://doi.org/10.1016/j.idcr.2021.e01358

Paul A, Singh S. Visceral leishmaniasis in the COVID-19 pandemic era. Trans R Soc Trop Med Hyg. 2023;117(2):67-71. https://doi.org/10.1093/trstmh/trac100

Janka GE, Lehmberg K. Hemophagocytic syndromes-An update. Blood Rev. 2014;28(4):135-42. https://doi.org/10.1016/j.blre.2014.03.002

Pereira ER, Santos JB, Silva ZS, Biazussi HM. Covid-19 e Infecções Simultâneas: uma revisão de literatura. Rev Multidiscipl Nordeste Mineiro. 2022;3(3).

Miguel DC, Brioschi MBC, Rosa LB, Minori K, Grazzia N. The impact of COVID-19 on neglected parasitic diseases: what to expect? Trends Parasitol. 2021;37(8):694-7. https://doi.org/10.1016/j.pt.2021.05.003

Mungroo MR, Khan NA, Siddiqui R. The increasing importance of the novel Coronavirus. Hosp Pract (1995). 2021;49(1):1-11. https://doi.org/10.1080/21548331.2020.1828888